Singapore markets open in 4 hours 42 minutes
  • Straits Times Index

    3,253.79
    -3.03 (-0.09%)
     
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • Dow

    34,152.01
    +239.57 (+0.71%)
     
  • Nasdaq

    13,102.55
    -25.50 (-0.19%)
     
  • BTC-USD

    23,961.07
    -92.76 (-0.39%)
     
  • CMC Crypto 200

    569.33
    -2.58 (-0.45%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Gold

    1,790.40
    -7.70 (-0.43%)
     
  • Crude Oil

    86.60
    -2.81 (-3.14%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • Nikkei

    28,868.91
    -2.87 (-0.01%)
     
  • Hang Seng

    19,830.52
    -210.34 (-1.05%)
     
  • FTSE Bursa Malaysia

    1,518.78
    +14.77 (+0.98%)
     
  • Jakarta Composite Index

    7,133.45
    +40.18 (+0.57%)
     
  • PSE Index

    6,850.64
    +112.80 (+1.67%)
     

DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MINNEAPOLIS, November 09, 2021--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 12th Annual Craig-Hallum Alpha Select Conference being held virtually on Tuesday, November 16, 2021. Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Its lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, DiaMedica has initiated and commenced enrollment in its ReMEDy Phase 2/3 trial in the treatment of AIS and is completing enrollment in its REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006141/en/

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
tim@lifesciadvisors.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting